GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate

GeoVax Labs Inc GOVX entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara vector expressing spike and nucleocapsid antigens of the SARS-CoV-2 virus.
GeoVax has exclusive rights to develop and commercialize a multi-antigenic SARS-CoV-2 vaccine candidate developed at the City of Hope for immunocompromised patients.
The financial terms of the transaction were not immediately disclosed.
The candidate is currently in Phase 2 trial and has shown potential to be used as a primary and/or general booster vaccine against COVID-19 worldwide.
The Phase 2 trial is assessing the safety and immunogenicity of COH04S1 compared to Pfizer Inc PFE / BioNTech SE's BNTX vaccine in patients who have previously received either an allogeneic or autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy.
Related Link: Why Geovax Labs Shares Are Soaring Today?
Price Action: GOVX shares are down 1.19% at $4.19 during the premarket session on the last check Wednesday.